# Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

> **NCT04685070** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 56 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage III

## Interventions

- **DRUG:** HS-10296 (Almonertinib)

## Key facts

- **NCT ID:** NCT04685070
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-14
- **Primary completion:** 2022-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04685070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04685070, "Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04685070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*